AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Eckert & Ziegler Strahlen- und Medizintechnik AG

Legal Proceedings Report May 11, 2001

130_rns_2001-05-11_bf5c754d-9e7a-4d1f-8996-91c85d2962c5.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 11 May 2001 10:29

Ad hoc-Service: Eckert & Ziegler AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Eckert & Ziegler Ends Legal Dispute Surrounding Major Project Receives New Order Valued at 14 Million Euro Berlin, 11.05.2001. On Thursday Eckert & Ziegler AG reached agreement with a major client in respect of a controversial production line project and on a one- off payment of approximately 2.5 million EUR as a compensation for work rendered. The project had become a bone of contention in winter 2000 when the client, as a result of changed market conditions, cancelled an order for a production line for permanent implants that had been placed two years before, and refused to confirm acceptance and effect payment of the completion instalments. As a result of the refusal to pay the final instalment, Eckert & Ziegler AG had been forced to issue a profit warning last year. In the agreement the client now also waived all rights of usage in respect of the disputed equipment. As a result, Eckert & Ziegler can now itself use the line for the production of permanent lowlevel radioactive palladium implants. These devices are used for the treatment of prostate tumours. ‘This settlement represents a fair compensation for Eckert & Ziegler AG’ explained Dr. Andreas Eckert, President and CEO of the company. ‘Moreover, with the line conflict resolved, both parties can now again concentrate on joint opportunities in the European market. As a consequence, the partner has awarded to Eckert & Ziegler, in addition to the payment of compensation, a five-year contract to supply iodine implants, valued at 14 million EUR. We are confident that this will further strengthen our leading position in the European market for cancer treatment radiation sources.’ The Board of Directors For further information please contact: Karolin Riehle, Investor Relations, Eckert & Ziegler AG Robert-Rössle-Str. 10, 13125 Berlin, www.ezag.com Tel.: (+49 30) 94 10 84-138, Fax.: (+49 30) 94 10 84-112 end of ad hoc announcement (c) DGAP 11.05.2001 ——————————————————————————– WKN: 565970; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 111029 Mai 01

Talk to a Data Expert

Have a question? We'll get back to you promptly.